Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Maintains No Change In APPROVe Results Despite Correction

This article was originally published in The Pink Sheet Daily

Executive Summary

The company corrected the description of statistical methods used in the Vioxx study.

You may also be interested in...



Vioxx Short-Term Risk Highlighted In NEJM Correction

NEJM analysis shows heart risk associated with rofecoxib may increase prior to 18 months of treatment.

Vioxx Short-Term Risk Highlighted In NEJM Correction

NEJM analysis shows heart risk associated with rofecoxib may increase prior to 18 months of treatment.

Merck’s Vioxx Extension Study Does Not Show An Increased Risk Of Heart Attack

Preliminary analysis shows that there was not a statistically significant difference in the risk of confirmed thrombotic cardiovascular events for patients previously on Vioxx compared to placebo.

Related Content

Topics

UsernamePublicRestriction

Register

PS064248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel